Bills · HR 1632
IN COMMITTEE· 119TH CONGRESS
House BillHR 1632Drug safety, medical device, and laboratory regulationCongressional oversight
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
INTRO FEB 26· LAST ACTION FEB 26
READING
6MIN
COSPONSORS
1
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because it fundamentally changes how certain medical products could reach American patients. If it becomes law, it could significantly accelerate the availability of new treatments by reducing the time and cost involved in the U.S. regulatory approval process. This could be particularly impactful during public health crises or for rare diseases where current treatment options are limited.
However, it also raises questions about the thoroughness of the FDA's review, which is currently known for its stringent safety and effectiveness standards. While it could bring new options to market faster, some may be concerned about whether relying on foreign approvals, even from trusted countries, coupled with a tight 30-day FDA review, sufficiently protects American consumers. The bill's provision allowing Congress to overrule FDA denials also shifts some power over scientific approval decisions from the agency to lawmakers.
KEY PROVISIONS
5AI-extractedPROVISION 01
Establishes a new pathway for "reciprocal marketing approval" for drugs, biological products, and devices if they are already approved and lawfully marketed in certain specified foreign countries (those listed in section 802(b)(1) or the United Kingdom).
This creates an entirely new, expedited route for products to enter the U.S. market, bypassing the full standard FDA review process.
PROVISION 02
Requires products seeking reciprocal approval to meet specific criteria, including having no prior safety concerns, and demonstrating a public health or unmet medical need in the United States.
These criteria aim to ensure that only products deemed safe and necessary by foreign regulators, and for which there is a clear U.S. need, can use this expedited pathway.
PROVISION 03
Mandates that the FDA make a decision (grant or decline approval) within 30 days of receiving a reciprocal marketing approval request.
This imposes a significantly faster timeline on the FDA than typical approval processes, potentially speeding up patient access but also limiting review time.
PROVISION 04
Allows the FDA to decline reciprocal approval if it determines the product is not safe or effective, or to require post-market safety studies as a condition of approval.
This provision retains some FDA authority to protect public health even within an expedited framework, allowing for U.S.-specific safety oversight.
PROVISION 05
Creates a mechanism for Congress to disapprove an FDA decision to deny reciprocal marketing approval, effectively forcing the product's approval.
This introduces a novel congressional check on FDA's scientific review decisions, potentially politicizing product approvals.
SPONSORSHIP
1 + 1
R· Texas
YRS IN OFFICE
7
BILLS LED
68
COSPONSOR BREAKDOWNBIPARTISAN · 0%
DEM 0 REP 1 IND 0
ACTION TIMELINE
2 EVENTSFEB 26
Introduced in House
FEB 26
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 1632
Congress119th
StatusIn Committee
IntroducedFeb 26, 2025
Last actionFeb 26, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · ENERGY AND COMMERCE COMMITTEE · INTRODUCED FEB 26, 2025
House BillHR 1632Drug safety, medical device, and laboratory regulationCongressional oversight
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
INTRODUCED FEB 26, 2025· LAST ACTION FEB 26, 2025
PASSAGE CHANCES
—%
READING
6 min
COSPONSORS
1
COMPLEXITY
Moderate
